Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

ACRP CP CERTIFICATION EXAM 2024- 2025 ACTUAL EXAM COMPLETE ACCURATE EXAM, Exams of Nursing

ACRP CP CERTIFICATION EXAM 2024- 2025 ACTUAL EXAM COMPLETE ACCURATE EXAM QUESTIONS WITH DETAILED VERIFIED ANSWERS (100% CORRECT ANSWERS) /ALREADY GRADED A+

Typology: Exams

2024/2025

Available from 01/04/2025

TutorSection
TutorSection 🇺🇸

3

(1)

621 documents

Partial preview of the text

Download ACRP CP CERTIFICATION EXAM 2024- 2025 ACTUAL EXAM COMPLETE ACCURATE EXAM and more Exams Nursing in PDF only on Docsity!

ACRP CP CERTIFICATION EXAM 2024-

2025 ACTUAL EXAM COMPLETE

ACCURATE EXAM QUESTIONS WITH

DETAILED VERIFIED ANSWERS (100%

CORRECT ANSWERS) /ALREADY

GRADED A+

A sponsor is developing an IP for treatment of a medical condition where there is one additional marketed product approved for treatment of the condition. The sponsor believes their product works as well or better than the current treatment with fewer side effects. What is the most-likely study design they will use to test the efficacy of the IP? - ....ANSWER...Non-Inferiority

What type of clinical trial most likely requires enrollment of the largest number of research subjects? - ....ANSWER...Therapeutic confirmatory (aka Pivotal Trial: Ph III: or Comparative Efficacy)

Minimum number of membors on an IRB/IEC - ....ANSWER...5 (... lay people and medical professionals can be part of the IRB/IEC)

Who is responsible for providing the protocol - ....ANSWER...The Sponsor

The purpose of the SIV is to - ....ANSWER...1. review standard procedures

  1. review the protocol
  2. review the blank eCRFs: Minimum SAE reporting requirements
  3. Subject details (ID not name)
  4. IP
  5. Interventions for the event that is being reported
  6. Details of the event
  7. Details on the reporter of the event
  8. Admin and sponsor or company details

Vulnerable subjects - ....ANSWER...1. Junior members of the medical profession

  1. Employees of a pharmaceutical company
  2. Military personnel
  1. Pregnant Women
  2. Prisoners

IRB/IEC Evaluates - ....ANSWER...1. The rights: safety: and well-being of the subjects participating in the trial

  1. The subject selection procedure
  2. The scientific tenability of the trial

Serious Adverse Event (SAE) - ....ANSWER...1. Results in death: is life threatening

  1. Requires inpatient admission
  2. Prolonged admission
  3. Congenital anomaly
  4. Persistent incapacity
  5. Death itself is not neccessarily an SAE*
  6. Must be reported by sponsor to authorities within 15 calendars days from sponsors first knowledge of the event

*Seriousness does not equal severity in that Serious requires reporting while severe may not.. Severe may just be used to describe an AE

Adverse Drug Reaction (ADR) - ....ANSWER...1. All noxious and unintended response that is related to any dose

  1. If the reaction is possibly: probably: or definitely related to the drug: it is considered an ADR
  2. All ADRs must be documented
  3. ADRs are not always AEs

Not observed before. Or the Event occurred more often than previously observed - ....ANSWER...Unexpected Event

Adverse Event (AE) - ....ANSWER...1. Any untoward medical occurrence that does not necessarily have a causal relationship with treatment

  1. Can be mild moderate or severe
  2. Worsening of a pre-existing medical condition is an AE

Non-Clinical Study - ....ANSWER...1. Not conducted on human subjects

  1. Provide preliminary safety and pharmacokinetic data needed to support studies in human

Data Safety and Monitoring Board (DSMB) - ....ANSWER...1. Assesses the progress of a clinical trial: the safety data: and the critical efficacy endpoints

  1. Can recommend that sponsors modify: end: or continue a trial. But cannot recommend they start a new trial

WMA - ....ANSWER...World Medical Association

Declaration of Helsinki - ....ANSWER...-Created by WMA in 1964: - Defines the ethical principles for medical research involving human subjects

  1. Importance of ICF Requirement of ethical review and approval of research before it is undertaken:
  2. Acknowledgement and guidance of special protections for vulnerable subjects:
  3. Recommends trials are registered on public database

LAR - ....ANSWER...Legally Acceptable Representative. (regarding consenting procedures)

International Conference on Harmonization (ICH) - ....ANSWER...Mission is to provide a unified standard for Europe: US: and Japan to facilitate the acceptance of clinical trials

Expected AEs - ....ANSWER...Those that are consistent with the product information and were present on previous and preclinical trials

Contents of the site TMF - ....ANSWER...1. IP accountability records

  1. Subject screening log
  2. Signed ICFs

Per ICH: how long must an IRB/IEC keep correspondence for after the completion of a clinical trial - ....ANSWER...at least 3 years

The signature page is an optional section of the IB (T/F) - ....ANSWER...True

Incapacitated subjects can provide consent as soon as capacity is regained (T/F) - ....ANSWER...True

Who should send Annual Progress Reports to the IRB/IEC - ....ANSWER...The Investigator

The investigator is required to share names of subjects with the IRB/IEC (T/F) - ....ANSWER...False

CRAs(monitors) cannot review source documents of subjects who have withdrawn consent. Even if the source document predates their consent withdrawal(T/F) - ....ANSWER...True

When should research studies involving human subjects be registered in a publicly accessible database - ....ANSWER...before recruiting the first subject

Any changes to safety language in an IB should be submitted to the IRB/IEC (T/F) - ....ANSWER...True

All SAE's must be life-threatening to be considered an SAE opposed to AE (T/F) - ....ANSWER...True

After completion of a study: where should the final trial close-out monitoring report prepared by the CRA be filed? - ....ANSWER...in the Sponsor's files

During a multi-site clinical study: Whose responsibility is it to report subject recruitment rate?

  • ....ANSWER...CRA (Monitor)

What is the investigator's first priority when a subject wishes to withdraw prematurely from the trial? - ....ANSWER...to obtain the subject's reason for withdrawal

CRC's can't adjust IP dose: even if they are a qualified physician (T/F) - ....ANSWER...False. If a CRC is a qualified physician they can adjust IP dose

Following unblinding in the case of a suspected serious unexpected adverse drug reaction: the treatment assigned to the subject turns out to be the comparator product. Who should the sponsor inform? - ....ANSWER...The manufacturer of the product and/or the regulatory authorities

If there is a a serious unexpected adverse drug reaction in a blinded trial: when should the investigator unblind the subject? - ....ANSWER...The investigator unblinds before reporting the SUADR: in order to determine a safe treatment

What would be the first priority for an investigator when a subject wishes to withdraw prematurely from the trial? - ....ANSWER...Try to obtain the subject's reason for withdrawal.

CRO recently switched from paper CRF to an EDC system. The EDC system must conform to the established requirements for - ....ANSWER...Validation

Accuracy

Reliability

Completeness

Part of a sponsor's responsibility pertaining to electronic trial data handling is to - ....ANSWER...maintain an audit trail, data trail, and edit trail.

A research subject's responsibilities for study participation should be described in the - ....ANSWER...ICF

What document would an investigator reference to learn more about the previous clinical and nonclinical results of studies of the IP? - ....ANSWER...Investigators brochure

During a multi site clinical study: whose responsibility is it to report subject recruitment rate?

  • ....ANSWER...The CRA

An unconscious adult subject was enrolled in a study after obtaining consent from an LAR: and protocol therapy was initiated. The subject showed significant improvement in his clinical condition: and regained consciousness. The Investigator should inform the subject about the study and - ....ANSWER...Obtain consent from the subject for the study

A site is in the start up phase of an industry sponsored phase 3 trial: and has received IRB approval. The site can begin enrolling subjects

after... - ....ANSWER...A signed clinical trial agreement between the site and sponsor is in place.

A site is screening potential subjects for a study looking at mild cognitive impairment. One of the inclusion criteria is a score of 25 or less on a psychometric test: a research specific tool which measures cognitive ability. Which of the following individuals can administer the psychometric test to the potential subjects? - ....ANSWER...A research assistant who is certified to administer the psychometric test

A research study: in which there is no intended clinical benefit to the subject: is being submitted to the IRB. What benefit information should be included in the ICF? - ....ANSWER...Wording indicating that there is no expected benefit should be included

A CRA notices during an onsite visit that the date on IRB approval letter for a protocol is prior to the effective date indicated on the cover page of the protocol and the signatures of the investigator and sponsor. What should the CRA do FIRST? - ....ANSWER...Confirm dates of initial receipt of the sponsor protocol and the IRB submission dates.

In a multi arm: randomized clinical trial: one arm of the protocol was terminated due to an increased risk of cancer in subjects. Who is responsible for providing a written report to the IRB? - ....ANSWER...PI

Which of the following required elements should be included in a clinical trial protocol? - ....ANSWER...Subject inclusion and exclusion criteria

Prior to archiving a study: documentation of IP destruction at the site should be filed in the study files of the - ....ANSWER...PI and Sponsor

During a monitoring visit: what records would a CRA reference to verify a subject's compliance to the study visit schedule and assessments? - ....ANSWER...Electronic medical record

When considering participation in a study: the investigator should determine if he... - ....ANSWER...Sees enough patients who would qualify for the study

New safety information has become available from the Sponsor about the IP being used in a clinical trial. The investigator must - ....ANSWER...Submit a revised ICF to the IRB noting the new safety information

Per ICH: an IRB must keep correspondence for at least how long after the completion of a clinical trial? - ....ANSWER...3 Years

When would an impartial witness be needed during the consent process for an illiterate subject? - ....ANSWER...To observe the consent process

A study which seeks to determine the ideal dose and regimen of a new IP to treat hypothyroidism is considered to be - ....ANSWER...Phase II

After completion of a study: the final trial close out monitoring report prepared by the CRA should be filed in which of the following stakeholder files? - ....ANSWER...The sponsors files

A blood sample collection is required to screen for bloodborne pathogens before subject could be

enrolled in a study. Where will subjects find information of the procedures and any foreseeable risks or inconveniences? - ....ANSWER...ICF

When should a research study involving human subjects be registered in a publicly accessible database? - ....ANSWER...Before recruiting the first subject

In the case of an incapacitated subject: who should receive a copy of the signed and dated ICF? - ....ANSWER...The subjects legally acceptable representative

A medical student is approaches by a faculty member for possible participation in a cricothyroidotomy simulation research study. Which of the following increases risk to the study? - ....ANSWER...Consenting in the presence of figure of authority

The clinical trial phase that focuses on safety and human pharmacology in healthy volunteers - ....ANSWER...Phase I

Who is ultimately responsible for all aspects of the research conducted at a site? - ....ANSWER...Principal investigator

An international quality standard that is provided by ICH E6(R2) describing safety: accuracy of trials and credibility of data - ....ANSWER...GCP

What event resulted in the Nuremburg Cod of 1949 - ....ANSWER...Nazi Medical Experiments

Prior to archiving a study: documentation of IP destruction at the site should be filed in the study files of the - ....ANSWER...PI and Sponsor

In the case of an incapacitated subject: who should receive a copy of the signed and dated ICF? - ....ANSWER...The subject's legally acceptable representative

Which of the following required elements should be included in a clinical trial protocol? - ....ANSWER...The subject inclusion and exclusion criteria

During a multi-site clinical study: whose responsibility is it to report subject recruitment rate?

  • ....ANSWER...The CRA

A study which seeks to determine the ideal dose and regimen of a new IP to treat hypothyroidism is considered to be - ....ANSWER...Phase II

What document would an investigator reference to learn more about the previous clinical and nonclinical results of studies of the IP? - ....ANSWER...IB

When considering participation in a study: the investigator should determine if he/she - ....ANSWER...sees enough patients who would qualify for the study

When would an impartial witness be needed during the consent process for an illiterate subject? - ....ANSWER...To observe the consent process

During a monitoring visit: what records would a CRA reference to verify a subject's compliance to the study visit schedule and assessments? - ....ANSWER...electronic medical record

A site is screening potential subjects for a study looking at mild cognitive impairment. One of the inclusion criteria is a score of 25 or less on a psychometric test: a research-specific tool which measures cognitive ability. Which of the following individuals can administer the psychometric test to the potential subjects? - ....ANSWER...A research assistant who is certified to administer the psychometric test

A research study: in which there is no intended clinical benefit to the subject: is being submitted to the IRB/IEC. What benefit information should be included in the ICF? - ....ANSWER...Wording indicating that there is no expected benefit should be included.

A research subject's responsibilities for study participation should be described in the - ....ANSWER...ICF

New safety information has become available from the Sponsor about the IP being used in a clinical trial. The Investigator must - ....ANSWER...submit a revised ICF to the IRB/IEC noting the new safety information.

A medical student is approached by a faculty member for possible participation in a cricothyroidotomy simulation research study. Which of the following increases risk to the subject? - ....ANSWER...Consenting in the presence of figure of authority

What would be the first priority for an investigator when a subject wishes to withdraw prematurely from the trial? - ....ANSWER...Try to obtain the subject's reason for withdrawal.

A blood sample collection is required to screen for bloodborne pathogens before subject could be enrolled in a study. Where will subjects find information of the procedures and any foreseeable risks or inconveniences? - ....ANSWER...ICF

Per ICH: an IRB/IEC must keep correspondence for at least how long after the completion of a clinical trial? - ....ANSWER...3 years

A CRA notices during an onsite visit that the date on IRB/IEC approval letter for a protocol is prior to the effective date indicated on the cover page of the protocol and the signatures of the investigator and sponsor. What should the CRA do FIRST? - ....ANSWER...Confirm dates of initial receipt of the sponsor protocol and the IRB/IEC submission dates.

A CRO recently switched from paper CRF to an EDC system. The EDC system must conform to the established requirements for - ....ANSWER...validation, accuracy, reliability, and completeness.

When should a research study involving human subjects be registered in a publicly accessible database? - ....ANSWER...Before recruiting the first subject

An unconscious adult subject was enrolled in a study after obtaining consent from an LAR: and

protocol therapy was initiated. The subject showed significant improvement in his clinical condition: and regained consciousness. The Investigator should inform the subject about the study and - ....ANSWER...obtain consent from the subject for the study.

After completion of a study: the final trial close-out monitoring report prepared by the CRA should be filed in which of the following stakeholder files? - ....ANSWER...The sponsor's files

A site is in the start-up phase of an industry- sponsored phase 3 trial: and has received IRB/IEC approval. The site can begin enrolling subjects after

  • ....ANSWER...a signed clinical trial agreement between the site and sponsor is in place.

In a multi-arm: randomized clinical trial: one arm of the protocol was terminated due to an increased risk of breast cancer in the subjects. Who is responsible for providing a written report to the IRB/IEC? - ....ANSWER...PI

Part of a sponsor's responsibility pertaining to electronic trial data handling is to maintain an audit trail: data trail: and edit trail. Which entity is primarily charged with considering subject rights and well-being during clinical trials? - ....ANSWER...Institutional Review Board (IRB)/Independent Ethics Committee (IEC)

Which of the following would be considered a vulnerable population requiring special consideration by an IRB/IEC? - ....ANSWER...1. Medical, pharmacy, dental, and nursing students:

  1. Prisoners
  2. Serving military personnel

T or F- The terms "serious" and "severe" are synonymous according to ICH - ....ANSWER...False

An Unexpected Adverse drug reaction is - ....ANSWER...A reaction that is not consistent with the applicable product information

ICH safety definitions can be found in - ....ANSWER...ICH E2A

An Adverse Event (AE) that is severe in intensity - ....ANSWER...May not meet the definition of serious

T or F- Information discovered during the course of a clinical investigation that might materially influence the benefit-risk assessment of the investigation/product may necessitate rapid communication to regulatory authorities. - ....ANSWER...True

Subject 3826 had to stay in the hospital for three extra days when his legs started swelling after participation in a cardiac drug study. Swelling of the legs was listed in the Investigator's Brochure as a possible side effect. This is considered a/an - ....ANSWER...Serious Adverse Drug Reaction

T or F- A subject in your diabetes research study developed colon cancer: which the Investigator has determined to be unrelated to the study. The subject is currently asymptomatic. This will be considered a serious adverse event because it is life threatening.

  • ....ANSWER...False

In pre-market approval studies: all noxious and unintended responses to a medicinal product even possibly related to any dose should be considered - ....ANSWER...Adverse Drug Reaction

You were just informed that you have a research patient that is receiving intensive treatment in an emergency room for allergic bronchospasm. This should be considered as - ....ANSWER...A serious adverse event

After a Serious Adverse Event (SAE) has occurred: how should you list the subject identification on the immediate and follow-up reports? - ....ANSWER...By their subject identification number

In which scenario would unblinding typically occur? - ....ANSWER...When the investigator wants to make sure a particular subject is not randomized to placebo in the case of a Serious Adverse Event (SAE)

What is the timeframe for "expedited" reporting of serious: fatal or life-threatening: unexpected adverse drug reactions to regulatory authorities? -

....ANSWER...As soon as possible, but no later than SEVEN calendar days after first knowledge of the event

The term "severe" in ICH is used to describe - ....ANSWER...The Intensity of a specific event

All cases judged by either the reporting health care professional or the sponsor as having a reasonable suspected causal relationship to the medicinal product qualify as - ....ANSWER...Adverse Drug Reactions

Which of the following criteria is described in ICH- GCP as necessary for classifying an Adverse Event (AE) as an Adverse Drug Reaction (ADR)? - ....ANSWER...That a causal relationship is at least a reasonable possibility

A subject has a suspected serious adverse drug reaction with the outcome of death. Which are items that should be submitted to the Sponsor? - ....ANSWER...1. A de-identified autopsy report: if available

  1. Cause of death: and a comment on its possible relationship to the suspected drug reaction

What is the purpose of an initiation visit? - ....ANSWER...1. To review the protocol

  1. To review research site's SOPs
  2. To review the blank CRFs

The process by which a subject voluntarily confirms his or her willingness to participate in a clinical trial is known as - ....ANSWER...Informed Consent Process

T or F- The IRB/IEC may request additional information be given to subjects when: in the judgment of the IRB/IEC: it would add meaningfully to the protection of the rights: safety and/or well- being of the subjects. - ....ANSWER...True

The IRB/IEC should consist of a reasonable number of members: who collectively have the qualifications and experience to review and evaluate the science: medical aspects: and ethics of the proposed trial. It is recommended that the IRB/IEC should include - ....ANSWER...1. At least five members